Results 111 to 120 of about 6,300,245 (266)

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

A hybrid lentivirus-transposon vector for safer gene therapy [PDF]

, 2010
Gene therapy vectors based on the HIV-1 lentivirus are an attractive option for clinical applications because they enter a broad range of target cells efficiently and deliver stable gene expression through integration into host chromosomes.
Vink, C.A.
core  

The promise of gene therapy for the treatment of alpha-1 antitrypsin deficiency

, 2012
In the last 13 years, three gene therapy trials for the treatment of alpha-1 antitrypsin deficiency have been conducted. The first trial delivered plasmid encoding the alpha-1 antitrypsin cDNA to the nasal epithelium using cationic liposomes.
Flotte, Terence R., Cruz, Pedro E., Mueller, Christian   +2 more
core   +1 more source

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

FEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés, Luise Franz, Christian P.R. Hackenberger   +2 more
wiley   +1 more source

Liberating Gene Therapy

, 1999
review of THE ETHICS OF HUMAN GENE THERAPY, by LeRoy Walters and Julie Gage ...
Rehmann-Sutter, Christoph
core  

Corrigendum: Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy

Frontiers in Medicine, 2023
Reetta A. E. Eriksson, Reetta A. E. Eriksson, Tiina Nieminen, Lionel Galibert, Sanna K. Peltola, Petra Tikkanen, Piia Käyhty, Piia Käyhty, Hanna M. Leinonen, Igor Oruetxebarria, Saana Lepola, Anniina J. Valkama, Eevi M. Lipponen, Hanna P. Lesch, Seppo Ylä-Herttuala, Seppo Ylä-Herttuala, Kari J. Airenne   +16 more
doaj   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Gene Therapy: Into the Home Stretch

, 1990
and ADA Gene Therapy Enters the Competition ...
Culliton, Barbara J.
core  

Polycation-Based Gene Therapy: Current Knowledge and New Perspectives

, 2011
At present, gene transfection insufficient efficiency is a major drawback of non-viral gene therapy. The 2 main types of delivery systems deployed in gene therapy are based on viral or non-viral gene carriers.
Winnik, Francoise M., Fernandes, Julio C., Shi, Qin, Tiera, Marcio J.   +3 more
core   +1 more source